Markers of vascular disease in plasma from patients with chronic kidney disease identified by proteomic analysis

Journal of Hypertension

Volumn 29, Issue 4, 2011, Pages 783-790

  Schiffer, Eric ^a   Liabeuf, Sophie ^b,c   Lacroix, Chrystelle ^d,e   Temmar, Mohamed ^c   Renard, Cedric ^c   Monsarrat, Bernard ^d,e   Choukroun, Gabriel ^b   Lemke, Horst Dieter ^f   Vanholder, Raymond ^g   Mischak, Harald ^a   Massy, Ziad A ^b,c  

^a MOSAIQUES DIAGNOSTICS GMBH   (Germany)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

^d INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^e UNIVERSITÉ PAUL SABATIER   (France)

^f eXcorLab GmbH   (Germany)

^g GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

arteriosclerosis; atherosclerosis; collagen; peptides; plasma

Indexed keywords

APOLIPOPROTEIN C3; BIOLOGICAL MARKER; COLLAGEN; COLLAGEN ALPHA 1 TYPE 1; COLLAGEN ALPHA 1 TYPE 3; UNCLASSIFIED DRUG;

AGED; ARTERIAL STIFFNESS; ARTERY CALCIFICATION; ARTICLE; ATHEROSCLEROSIS; CAPILLARY ELECTROPHORESIS; CAPILLARY ELECTROPHORESIS COUPLED MASS SPECTROMETRY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MASS SPECTROMETRY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY;

EID: 79952753705     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283441129     Document Type: Article

References (45)

1. Verhave JC, Hillege HL, Burgerhof JG, Gansevoort RT, de Zeeuw D, de Jong PE, et al. The association between atherosclerotic risk factors and renal function in the general population. Kidney Int 2005; 67:1967-1973. (Pubitemid 40577733)
2. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20:1048-1056. (Pubitemid 40862092)
3. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 2000; 35 (4 Suppl 1):S117-S131. (Pubitemid 30183825)
4. Culleton BF, Wilson PW. Cardiovascular disease: risk factors, secular trends, and therapeutic guidelines. J Am Soc Nephrol 1998; 9 (12 Suppl):S5-S15.
5. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008; 3:505-521.
6. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4:1551-1558.
7. Liabeuf S, Barreto DV, Barreto FC, Meert N, Glorieux G, Schepers E, et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 2010; 25:1183-1191.
8. Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008; 51:395-406. (Pubitemid 351273480)
9. Temmar M, Liabeuf S, Renard C, Czernichow S, Esper NE, Shahapuni I, et al. Pulse wave velocity and vascular calcification at different stages of chronic kidney disease. J Hypertens 2010; 28:163-169.
10. Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension 1995; 26:485-490.
11. Zureik M, Temmar M, Adamopoulos C, Bureau JM, Courbon D, Thomas F, et al. Carotid plaques, but not common carotid intima-media thickness, are independently associated with aortic stiffness. J Hypertens 2002; 20:85-93. (Pubitemid 34913406)
12. von Zur Muhlen C, Schiffer E, Zuerbig P, Kellmann M, Brasse M, Meert N, et al. Evaluation of urine proteome pattern analysis for its potential to reflect coronary artery atherosclerosis in symptomatic patients. J Proteome Res 2009; 8:335-345.
13. Girolami M, Mischak H, Krebs R. Analysis of complex, multidimensional datasets. Drug Discov Today Technologies 2007; 3:12-19.
14. Yang ZR. Biological applications of support vector machines. Brief Bioinform 2004; 5:328-338.
15. Weissinger EM, Wittke S, Kaiser T, Haller H, Bartel S, Krebs R, et al. Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int 2004; 65:2426-2434. (Pubitemid 38670029)
16. Yang ZR, Chou KC. Bio-support vector machines for computational proteomics. Bioinformatics 2004; 20:735-741. (Pubitemid 38443829)
17. DeLeo JM. Receiver operating characteristic laboratory (ROCLAB): software for developing decision strategies that account for uncertainty. Second International Symposium on Uncertainty Modeling and Analysis. 25-4-1993.
18. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99:2434-2439. (Pubitemid 29218240)
19. London GM, Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME. Arterial wave reflections and survival in end-stage renal failure. Hypertension 2001; 38:434-438. (Pubitemid 34225679)
20. London GM. Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol 2003; 14. (9 Suppl 4):S305-S309. (Pubitemid 37052395)
21. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361:827-833. (Pubitemid 36331846)
22. Schurgers LJ, Barreto DV, Barreto FC, Liabeuf S, Renard C, Magdeleyns EJ, et al. The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol 2010; 5:568-575.
23. Good DM, Wirtala M, McAlister GC, Coon JJ. Performance characteristics of electron transfer dissociation mass spectrometry. Mol Cell Proteomics 2007; 6:1942-1951. (Pubitemid 350213868)
24. Good DM, Coon JJ. Advancing proteomics with ion/ion chemistry. Biotechniques 2006; 40:783-789. (Pubitemid 46534919)
25. Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 2006; 7:230-240. (Pubitemid 43286453)
26. Gebauer P, Beckers JL, Bocek P. Theory of system zones in capillary zone electrophoresis. Electrophoresis 2002; 23:1779-1785. (Pubitemid 34752850)
27. Li J, Wang C, Kelly JF, Harrison DJ, Thibault P. Rapid and sensitive separation of trace level protein digests using microfabricated devices coupled to a quadrupole: time-of-flight mass spectrometer. Electrophoresis 2000; 21:198-210. (Pubitemid 30032714)
28. Li J, LeRiche T, Tremblay TL, Wang C, Bonneil E, Harrison DJ, et al. Application of microfluidic devices to proteomics research: identification of trace-level protein digests and affinity capture of target peptides. Mol Cell Proteomics 2002; 1:157-168.
29. Zimmerli LU, Schiffer E, Zürbig P, Kellmann M, Mouls L, Pitt A, et al. Urinary proteomics biomarkers in coronary artery disease. Mol Cell Proteomics 2008; 7:290-298. (Pubitemid 351298443)
30. Delles C, Schiffer E, von Zur MC, Peter K, Rossing P, Parving HH, et al. Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. J Hypertens 2010; 28:2316-2322.
31. Lee RT, Libby P. The unstable atheroma. Arterioscler Thromb Vasc Biol 1997; 17:1859-1867. (Pubitemid 28057082)
32. Murshed M, Harmey D, Millan JL, McKee MD, Karsenty G. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev 2005; 19:1093-1104. (Pubitemid 40632454)
33. Kalela A, Koivu TA, Sisto T, Kanervisto J, Hoyhtya M, Sillanaukee P, et al. Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease. Scand J Clin Lab Invest 2002; 62:337-342.
34. Noji Y, Kajinami K, Kawashiri MA, Todo Y, Horita T, Nohara A, et al. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med 2001; 39:380-384. (Pubitemid 32529917)
35. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112:1776-1784. (Pubitemid 38063698)
36. Maeda N, Li H, Lee D, Oliver P, Quarfordt SH, Osada J. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem 1994; 269:23610-23616. (Pubitemid 24293564)
37. Chan DC, Chen MM, Ooi EM, Watts GF. An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor? Int J Clin Pract 2008; 62:799-809. (Pubitemid 351533666)
38. Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM. Apolipoprotein CIII induces expression of vascular cell adhesion molecule- 1. in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 2006; 114:681-687. (Pubitemid 44252310)
39. Kawakami A, Osaka M, Tani M, Azuma H, Sacks FM, Shimokado K, et al. Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction. Circulation 2008; 118:731-742.
40. Kawakami A, Osaka M, Aikawa M, Uematsu S, Akira S, Libby P, et al. Tolllike receptor 2 mediates apolipoprotein CIII-induced monocyte activation. Circ Res 2008; 103:1402-1409.
41. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000; 102:1886-1892.
42. Lee SJ, Campos H,Moye LA, Sacks FM. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol 2003; 23:853-858. (Pubitemid 36566177)
43. Onat A, Hergenc G, Sansoy V, Fobker M, Ceyhan K, Toprak S, et al. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis 2003; 168:81-89. (Pubitemid 36555814)
44. Moberly JB, Attman PO, Samuelsson O, Johansson AC, Knight-Gibson C, Alaupovic P. Alterations in lipoprotein composition in peritoneal dialysis patients. Perit Dial Int 2002; 22:220-228. (Pubitemid 34546334)
45. Bredie SJ, Westerveld HT, Knipscheer HC, de Bruin TW, Kastelein JJ, Stalenhoef AF. Effects of gemfibrozil or simvastatin on apolipoprotein- Bcontaining lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia. Neth J Med 1996; 49:59-67. (Pubitemid 26276093)